Collaboration and License Agreements - Additional Information (Details) - USD ($) $ in Thousands			1 Months Ended	12 Months Ended
	May 08, 2023	Mar. 31, 2020	Mar. 31, 2020	Dec. 31, 2024	Dec. 31, 2023
Collaboration And License Agreements [Line Items]
Collaboration and license revenue				$ 2,816	$ 21,049
Incurred costs				137,637	114,507
Deferred revenue, current portion				11,698	10,137
Long-term deferred revenue				$ 1,246	$ 5,622
Maximum | Novartis Agreement
Collaboration And License Agreements [Line Items]
Ownership Interest				10.00%	10.00%
Minimum | Novartis Agreement
Collaboration And License Agreements [Line Items]
Ownership Interest		10.00%	10.00%
Amgen Inc. | Amgen Agreement
Collaboration And License Agreements [Line Items]
License agreement date	May 08, 2023
Upfront payment receivable	$ 30,000
Potential milestone payment	$ 500,000
Expects research term	3 years
Collaboration and license revenue				$ 2,800	$ 14,200
Deferred revenue				12,900
Long-term deferred revenue				$ 1,200
Novartis
Collaboration And License Agreements [Line Items]
License agreement date			Mar. 31, 2020
Upfront payment receivable		$ 20,000	$ 20,000
Collaboration and license revenue					5,800
Reimbursement cost					$ 1,900
Novartis | Research Funding
Collaboration And License Agreements [Line Items]
Upfront payment received			$ 10,000